share_log

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Benzinga ·  Mar 17 10:54

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 374
Write a comment